¼¼°èÀÇ ½Å°æÁ¶Àý ½ÃÀå : ±â¼úº°, ÀÚ±Ø À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2030³â)
Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030
»óǰÄÚµå : 1822290
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 367 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,014,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,423,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,549,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ½Å°æÁ¶Àý ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ Áß¿¡ 9.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾î 2025³â 68¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 106¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2030³â
±âÁØ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2025-2030³â
°ËÅä ´ÜÀ§ ±Ý¾×(10¾ï ´Þ·¯)
ºÎ¹® ±â¼úº°, ÀÚ±Ø À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡, »õ·Î¿î ½Å°æÁ¶Àý ±â¼ú °³¹ß, ³ëÀÎ Àα¸ Áõ°¡ µîÀ¸·Î ½Å°æÁ¶Àý ½ÃÀåÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æÀýÁ¦¼úÀÇ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

Neuromodulation Market-IMG1

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â º´¿ø ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Ŭ¸®´Ð ¹× ¹°¸®Ä¡·á ¼¾ÅÍ, ±âŸ ÃÖÁ¾ »ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù. 2024³â¿¡´Â º´¿ø ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º´¿ø ¹× ¿Ü·¡ ÀÇ·á ºÎ¹®Àº Á¾ÇÕÀûÀÌ°í ´ÙÇÐÁ¦ÀûÀÎ Ä¡·á¸¦ Á¦°øÇÏ°í °í±Þ ½Å°æÁ¶Àý¿ä¹ýÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ½Å°æÁ¶Àý¿ä¹ý ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ¿¡´Â Àü¹® ¼ö¼ú Àåºñ, ¼÷·ÃµÈ ÀÓ»óÀÇ, ÀÌ½Ä °¡´ÉÇÏ°í º¹ÀâÇÑ ½Å°æÀýÁ¦¼ú¿¡ ÇÊ¿äÇÑ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÌ °®Ãß¾îÁ® ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ø°ú ¿Ü·¡ ¼¾ÅÍ´Â ÀÌ¹Ì È®¸³µÈ »óȯ Á¦µµÀÇ ÇýÅÃÀ» ¹Þ°í Àֱ⠶§¹®¿¡ °í°¡ÀÇ ½Ã¼úÀ» ȯÀÚµéÀÌ ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼ºÁúȯ °ü¸®, ¼ö¼ú ÈÄ °ü¸®, ȯÀÚ ÃßÀû°ü¸®¿¡ ´ëÇÑ Á߿伺ÀÌ Á¡Á¡ ´õ °­Á¶µÊ¿¡ µû¶ó, ÀÌµé ±â°üÀº ½Ã¼ú·®ÀÌ ¸¹¾ÆÁö°í, ½Å°æÁ¶Àý Á¦°ø ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¸®´õ½ÊÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù.

½Å°æÁ¶Àý ±â¼ú ½ÃÀåÀº ³»ºÎ ½Å°æÁ¶Àý°ú ¿ÜºÎ ½Å°æÁ¶ÀýÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â ½Å°æÁ¶Àý ½ÃÀå¿¡¼­ ³»ºÎ ½Å°æÁ¶Àý ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³»ºÎ ½Å°æÁ¶ÀýÀº ƯÁ¤ ½Å°æ °æ·ÎÀÇ Ç¥Àû ÀÚ±ØÀ» ¿ëÀÌÇÏ°Ô ÇÏ´Â Á¤±³ÇÑ ±â¼ú·Î ÀÎÇØ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ Á¢±Ù¹ýÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ °úÁ¤Àº Åë°¢¼ö¿ë¼º ÅëÁõ, ÆÄŲ½¼º´, ¿ä½Ç±Ý, º¯½Ç±Ý µîÀÇ Áõ»óÀ» ¸¸¼ºÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. À̽ÄÇü ÀåÄ¡´Â ÃæÀü½Ä ¶Ç´Â ¿À·¡ Áö¼ÓµÇ´Â ¹èÅ͸®, ¸ÂÃãÇü ÀÚ±Ø ÇÁ·ÎÅäÄÝ, Æó¼â ·çÇÁ Çǵå¹é ¸ÞÄ¿´ÏÁò, ¹«¼± ¿¬°á µîÀÇ Æ¯Â¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉÀ» ÅëÇØ ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú ¸ÂÃãÇü Ä¡·á Á¶Á¤À» ÅëÇØ ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀº ħ½À¼ºÀ» ÃÖ¼ÒÈ­ÇÏ´Â ÄÄÆÑÆ®ÇÑ ÀåÄ¡ ¼³°è¸¦ Áö¿øÇÏ¿© ȯÀÚÀÇ Æí¾ÈÇÔ°ú Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, Àç·á °úÇÐ, Àü±Ø ¾ÆÅ°ÅØÃ³, ¼ÒÇÁÆ®¿þ¾î ¾Ë°í¸®ÁòÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀ» ÅëÇØ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ È¿À²¼º, ¾ÈÀü¼º ¹× ¼ö¸íÀÌ Áö¼ÓÀûÀ¸·Î °³¼±µÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ÀÓ»ó ÇöÀå¿¡¼­´Â ºñħ½ÀÀû ÁßÀ纸´Ù ü³» ½Å°æÁ¶Àý¼úÀÌ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

¼¼°è ½Å°æÁ¶Àý ½ÃÀåÀº 5°³ Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«)À¸·Î ³ª´¹´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½Å°æÁúȯ ¹× ¸¸¼ºÅëÁõÁúȯ Áõ°¡À², Áß±¹, Àεµ, ÀϺ» µîÀÇ ±¹°¡¿¡¼­ ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î ÀÎÇØ ½Å°æÁ¶Àý ½ÃÀå¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â Áö¿ªÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ´õ ³ªÀº »óȯ Á¤Ã¥ ¹× ÀÇ·á±â±â Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÈûÀÔ¾î ÷´Ü ½Å°æÁ¶Àý ±â¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Àα¸ Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¼¼°è ¹× ÇöÁö Àåºñ Á¦Á¶¾÷üÀÇ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Àü¹® Ä¡·á ¼¾ÅÍÀÇ ¼³¸³ÀÌ ÃËÁøµÇ°í Àúħ½ÀÀûÀ̰í ÀÌ½Ä °¡´ÉÇÑ Á¦Ç°ÀÌ Á¡Â÷ÀûÀ¸·Î äÅõǰí ÀÖ´Â °Íµµ ÀÌ Áö¿ª¿¡¼­ ½Å°æÁ¶ÀýÀÇ »ç¿ëÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àεµ, ű¹, ½Ì°¡Æ÷¸£ µîÀÇ ±¹°¡¿¡¼­ ÀÇ·á°ü±¤ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¼ú °Ç¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ¼ö¼ú ÈÄ °ü¸® ¹× ½Å°æÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ½Å°æÁ¶Àý(Neuromodulation) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ±â¼úº°/ÀÚ±Ø À¯Çüº°/¿ëµµº°/ÃÖÁ¾»ç¿ëÀÚº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÇÁ¸®¹Ì¾ö ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ½Å°æÁ¶Àý ½ÃÀå(±â¼úº°)

Á¦7Àå ½Å°æÁ¶Àý ½ÃÀå(ÀÚ±Ø À¯Çüº°)

Á¦8Àå ½Å°æÁ¶Àý ½ÃÀå(¿ëµµº°)

Á¦9Àå ½Å°æÁ¶Àý ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦10Àå ½Å°æÁ¶Àý ½ÃÀå(Áö¿ªº°)

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsTechnology, Stimulation Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.

Neuromodulation Market - IMG1

"The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period."

By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.

"The internal neuromodulation accounted for the largest market share in the neuromodulation market."

The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.

"The Asia Pacific is the fastest-growing region of the neuromodulation market by region."

The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.

A breakdown of the primary participants referred to for this report is provided below:

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).

Research Coverage

This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.

Reasons to Buy the Report

The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.

This report provides insights into the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 NEUROMODULATION MARKET, BY TECHNOLOGY

7 NEUROMODULATION MARKET, BY STIMULATION TYPE

8 NEUROMODULATION MARKET, BY APPLICATION

9 NEUROMODULATION MARKET, BY END USER

10 NEUROMODULATION MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â